Published: 7:30am, 3 Mar 2025Updated: 7:33am, 3 Mar 2025
Retiree Li Chun underwent various treatments for lymphoma for nine years before a new “living drug” produced in Hong Kong finally made a difference.
Advertisement
The cancerous tumours she had lived with for so long began clearing up after she received treatment under a Chinese University of Hong Kong (CUHK) clinical trial last October.
A big, painful tumour on her thigh was gone within a week. No active cancer cells showed up in her body scan done in mid February.
“I don’t feel much pain and don’t have many problems,” the 73-year-old said, referring to the treatment. “Three words to describe it – quick, nice, great.”
She was among the first five Hong Kong cancer patients to undergo the clinical trial using locally manufactured chimeric antigen receptor T-cell (CAR-T) products.
Advertisement
The others are a girl, five, a boy, 15, a man, 67, and a woman, 71. All are doing well and four were discharged from hospital two to four weeks after receiving the CAR-T infusion.